Shukra Pharmaceuticals Ltd

AI

Shukra Pharmaceuticals Ltd

₹ 41.4 0.41%
14 Aug - close price
About

Incorporated in 1993, Shukra Pharmaceuticals Ltd manufactures and markets pharmaceutical products, and does laboratory testing[1]

Key Points

Business Overview:[1][2]
SPL is a is WHO-GMP certified integrated manufacturer of formulations like tablet, capsules and small volume parenteral. It has assisted in the development and manufacture
of a variety of drugs and dosage forms and potency variations for many pharmaceutical companies

  • Market Cap 1,821 Cr.
  • Current Price 41.4
  • High / Low 65.3 / 17.1
  • Stock P/E 53.6
  • Book Value 2.05
  • Dividend Yield 0.02 %
  • ROCE 36.9 %
  • ROE 28.9 %
  • Face Value 1.00
Unsung hero
Maninder Nath Banerjee
He began a hunger strike at Fatehgarh jail for better treatment of political prisoners. After 66 days without food, he died on 20 June 1934.
Unsung hero
Parbati Giri
She joined the freedom movement at 11 and was imprisoned during the Quit India Movement at 16. She later devoted her life to orphans, women and rural communities.

Pros

  • Company is almost debt free.

Cons

  • Stock is trading at 20.2 times its book value
  • Debtor days have increased from 123 to 148 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
11 13 5 6 39 6 24
7 6 4 6 12 6 4
Operating Profit 4 7 1 -0 27 1 19
OPM % 37% 55% 24% -7% 69% 11% 81%
1 1 1 2 1 1 1
Interest 0 0 0 0 0 0 0
Depreciation 1 1 1 1 1 1 1
Profit before tax 4 8 1 0 27 0 18
Tax % 23% 29% 26% -1,090% 24% 553% 29%
3 5 1 2 20 -2 13
EPS in Rs 0.07 0.12 0.02 0.05 0.46 -0.04 0.29
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2025 Mar 2026 TTM
33 57 75
20 28 28
Operating Profit 13 29 47
OPM % 39% 51% 62%
4 5 4
Interest 1 1 1
Depreciation 3 3 4
Profit before tax 13 29 46
Tax % 28% 23%
10 22 34
EPS in Rs 0.22 0.50 0.76
Dividend Payout % 0% 2%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 74%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 130%
Stock Price CAGR
10 Years: 67%
5 Years: 157%
3 Years: 139%
1 Year: 131%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: 29%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2025 Mar 2026
Equity Capital 44 44
Reserves 19 46
4 5
20 23
Total Liabilities 87 117
19 22
CWIP 2 12
Investments 0 0
65 84
Total Assets 87 117

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2025 Mar 2026
8 4
-1 -14
-5 4
Net Cash Flow 2 -6
Free Cash Flow 5 -12
CFO/OP 92% 19%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2025 Mar 2026
Debtor Days 98 148
Inventory Days 447 320
Days Payable 414 232
Cash Conversion Cycle 131 236
Working Capital Days 403 352
ROCE % 37%

Insights

In beta
Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Revenue share - Commission Income (Other Operating Revenues)
% of revenue from operations ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Revenue share - Sale of Products (Manufacturing)
% of revenue from operations ・Standalone data
Revenue share - Sale of Services (Jobwork/Contract Manufacturing)
% of revenue from operations ・Standalone data
Revenue share - Sale of Trading (Traded goods)
% of revenue from operations ・Standalone data
Permanent employees on rolls
count ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Aug 2026
50.95% 50.95% 50.95% 50.95% 50.95% 50.95% 50.95% 50.95% 50.95% 50.95% 50.95% 51.16%
0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11%
48.93% 48.93% 48.93% 48.93% 48.93% 48.93% 48.93% 48.93% 48.93% 48.92% 48.93% 48.74%
No. of Shareholders 10,96312,97414,98916,32117,84418,23120,33721,44125,64927,17328,38428,384

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents